Kaken Pharmaceutical Co., Ltd. (TYO:4521)

Market Cap	180.89B
Revenue (ttm)	93.35B
Net Income (ttm)	20.53B
Shares Out	37.87M
EPS (ttm)	541.97
PE Ratio	8.81
Forward PE	23.46
Dividend	150.00 (3.13%)
Ex-Dividend Date	Mar 28, 2025

Volume	203,900
Average Volume	275,530
Open	4,790.00
Previous Close	4,823.00
Day's Range	4,738.00 - 4,795.00
52-Week Range	3,367.00 - 4,901.00
Beta	0.16
RSI	68.61
Earnings Date	May 9, 2025

About Kaken Pharmaceutical

Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast, a wound-healing agent; Ecclock for the treatment of primary axillary hyperhidrosis; Regroth, a periodontal regenerative agent; Hernicore for the treatment of lumbar disc herniation; and Seprafilm, an adhesion barrier used primarily in surger...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1917
• Employees: 1,135
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4521

Financial Performance

In 2023, Kaken Pharmaceutical's revenue was 72.04 billion, a decrease of -1.29% compared to the previous year's 72.98 billion. Earnings were 8.03 billion, an increase of 47.52%.